Retinoic acid receptor RXR-alpha, Developmental Studies Hybridoma Bank, PCRP-RXRA-2A8

Our team performed a comprehensive review of the scientific literature to identify studies using antibodies against human retinoic acid receptor RXR-alpha, followed by extraction and evaluation of available data according to pAbmAbs rating criteria.

YCharOS conducted a systematic head-to-head comparison of ten commercially available antibodies against retinoic acid receptor RXR-alpha across multiple applications.

Antibodies were tested by WB using lysates (100 µg protein) from HCT116 WT cells and retinoic acid receptor RXR-alpha deficient HCT116 (RXRA KO) cells . These cell lines were also used for IF. In addition, antibodies were evaluated by IP using HCT116 WT cell lysate (1 mg protein). All experiments were performed according to YCharOS standard protocols (see reference).

In WB (1:160 antibody dilution), PCRP-RXRA-2A8 failed to detect a band at the predicted size (~50 kDa) in HCT116 WT cell lysate. Two background bands of higher molecular weight were detected in both test lysates.

In IP, the antibody (1µg) did not enrich retinoic acid receptor RXR-alpha upon precipitation. Retinoic acid receptor RXR-alpha levels in the starting material, unbound fraction, and precipitate were assessed by WB using the retinoic acid receptor RXR-alpha-specific antibody MA5-35265 (1:500)

In IF, the antibody (1:50 dilution) produced signal of comparable intensity from WT and KO cells.

We highly encourage other scientists to share their observations.